Table 1.
Correlation between clinicopathological parameters in uterine papillary serous carcinoma and human epidermal growth factor receptor type 2 and hormone receptor status
| Total no. patients | HER2 | Hormone receptor* | |||||
|---|---|---|---|---|---|---|---|
| Positive (n = 10) | Negative (n = 61) | P‐value | Positive (n = 37) | Negative (n = 34) | P‐value | ||
| Histologic subtype | |||||||
| Pure | 50 | 8 (80) | 42 (69) | 0.46 | 26 (70) | 24 (71) | 0.98 |
| Mixed | 21 | 2 (20) | 19 (31) | 11 (30) | 10 (29) | ||
| FIGO stage | |||||||
| I | 27 | 1 (10) | 26 (42) | 0.04 | 14 (38) | 13 (38) | 0.27 |
| II | 13 | 2 (20) | 11 (18) | 7 (19) | 6 (18) | ||
| III | 25 | 7 (70) | 18 (30) | 15 (40) | 10 (29) | ||
| IV | 6 | 0 (0) | 6 (10) | 1 (3) | 5 (15) | ||
| Myometrial invasion (%) | |||||||
| 0 | 10 | 0 (0) | 10 (16) | 0.10 | 7 (19) | 3 (9) | 0.12 |
| <50 | 28 | 3 (30) | 25 (41) | 17 (46) | 11 (32) | ||
| >50 | 33 | 7 (70) | 26 (43) | 13 (35) | 20 (59) | ||
| Lymph node metastasis | |||||||
| Positive | 13 | 2 (20) | 11 (18) | 0.35 | 2 (6) | 11 (32) | 0.005 |
| Negative | 30 | 6 (60) | 24 (39) | 16 (43) | 14 (41) | ||
| Unknown | 28 | 2 (20) | 26 (43) | 19 (51) | 9 (27) | ||
| Lymph–vascular space involvement | |||||||
| Positive | 35 | 7 (70) | 28 (46) | 0.15 | 13 (35) | 22 (65) | 0.012 |
| Negative | 36 | 3 (30) | 33 (54) | 24 (65) | 12 (35) | ||
| Recurrence | |||||||
| Yes | 34 | 9 (90) | 25 (41) | 0.0024 | 13 (35) | 21 (62) | 0.024 |
| No | 37 | 1 (10) | 36 (59) | 24 (65) | 13 (38) | ||
Data show the number of patients in each group, with percentages given in parentheses. *Hormone receptor expression was classified as positive when the patient was positive for either estrogen or progesterone receptors. HER2, human epidermal growth factor receptor type 2; FIGO, International Federation of Gynecology and Obstetrics.